BR112014018636A8 - Derivados de benzil sulfonamida úteis como inibidores de mogat-2 - Google Patents
Derivados de benzil sulfonamida úteis como inibidores de mogat-2Info
- Publication number
- BR112014018636A8 BR112014018636A8 BR112014018636A BR112014018636A BR112014018636A8 BR 112014018636 A8 BR112014018636 A8 BR 112014018636A8 BR 112014018636 A BR112014018636 A BR 112014018636A BR 112014018636 A BR112014018636 A BR 112014018636A BR 112014018636 A8 BR112014018636 A8 BR 112014018636A8
- Authority
- BR
- Brazil
- Prior art keywords
- mogat
- inhibitors
- derivatives useful
- sulfonamide derivatives
- benzyl sulfonamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
DERIVADOS DE BENZIL SULFONAMIDA ÚTEIS COMO INIBIDORES DE MOGAT-2. A presente invenção refere-se a compostos da Fórmula abaixo: e análogos do mesmo em que os vários grupos substituintes, R1, R2, R3, R4, R5 A, e X são descritos aqui; ou um sal farmacêutico do mesmo; um método de tratamento de uma condição tal como hipertrigliceridemia e um processo para preparação dos compostos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261592717P | 2012-01-31 | 2012-01-31 | |
EP12382432 | 2012-11-06 | ||
PCT/US2013/022870 WO2013116075A1 (en) | 2012-01-31 | 2013-01-24 | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014018636A2 BR112014018636A2 (pt) | 2017-06-20 |
BR112014018636A8 true BR112014018636A8 (pt) | 2017-07-11 |
Family
ID=47148691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014018636A BR112014018636A8 (pt) | 2012-01-31 | 2013-01-24 | Derivados de benzil sulfonamida úteis como inibidores de mogat-2 |
Country Status (27)
Country | Link |
---|---|
US (1) | US8575352B2 (pt) |
EP (1) | EP2809651B1 (pt) |
JP (1) | JP2015511232A (pt) |
KR (1) | KR20140106750A (pt) |
CN (1) | CN104066719B (pt) |
AP (1) | AP2014007794A0 (pt) |
AR (1) | AR089771A1 (pt) |
AU (1) | AU2013215468A1 (pt) |
BR (1) | BR112014018636A8 (pt) |
CA (1) | CA2859995A1 (pt) |
CL (1) | CL2014001861A1 (pt) |
CO (1) | CO7010839A2 (pt) |
CR (1) | CR20140322A (pt) |
DO (1) | DOP2014000178A (pt) |
EA (1) | EA201491276A1 (pt) |
ES (1) | ES2590929T3 (pt) |
GT (1) | GT201400167A (pt) |
HK (1) | HK1199025A1 (pt) |
IL (1) | IL233712A0 (pt) |
MA (1) | MA35886B1 (pt) |
MX (1) | MX2014008599A (pt) |
PE (1) | PE20141679A1 (pt) |
PH (1) | PH12014501711A1 (pt) |
SG (1) | SG11201404106QA (pt) |
TW (1) | TW201343629A (pt) |
WO (1) | WO2013116075A1 (pt) |
ZA (1) | ZA201404836B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
PE20141789A1 (es) | 2012-01-31 | 2014-11-19 | Lilly Co Eli | Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2 |
JP2016501844A (ja) | 2012-11-06 | 2016-01-21 | イーライ リリー アンド カンパニー | MoGAT−2阻害剤として有用な新規のベンジルスルホンアミド化合物 |
ES2879826T3 (es) | 2015-06-15 | 2021-11-23 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有mgat2抑制活性的縮合環衍生物 |
US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US20220135577A1 (en) | 2019-01-11 | 2022-05-05 | Shionogi & Co., Ltd. | Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1655283A1 (en) * | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
EP1659113A1 (en) * | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
EA200701035A1 (ru) * | 2004-11-10 | 2007-10-26 | Пфайзер Инк. | Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения |
CN101087771A (zh) * | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n-磺酰基氨基苄基-2-苯氧基乙酰胺化合物 |
KR20090051778A (ko) * | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
US8232282B2 (en) * | 2006-09-28 | 2012-07-31 | Dainippon Sumitomo Pharma Co., Ltd. | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same |
WO2008059335A1 (en) * | 2006-11-13 | 2008-05-22 | Pfizer Products Inc. | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof |
EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
WO2010095767A1 (en) * | 2009-02-23 | 2010-08-26 | Banyu Pharmaceutical Co.,Ltd. | Pyrimidin-4(3h)-one derivatives |
US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
PE20141789A1 (es) | 2012-01-31 | 2014-11-19 | Lilly Co Eli | Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2 |
-
2013
- 2013-01-21 AR ARP130100180A patent/AR089771A1/es unknown
- 2013-01-21 TW TW102102260A patent/TW201343629A/zh unknown
- 2013-01-24 EA EA201491276A patent/EA201491276A1/ru unknown
- 2013-01-24 AP AP2014007794A patent/AP2014007794A0/xx unknown
- 2013-01-24 KR KR1020147021127A patent/KR20140106750A/ko not_active Application Discontinuation
- 2013-01-24 CA CA2859995A patent/CA2859995A1/en not_active Abandoned
- 2013-01-24 PE PE2014001197A patent/PE20141679A1/es not_active Application Discontinuation
- 2013-01-24 JP JP2014555589A patent/JP2015511232A/ja not_active Ceased
- 2013-01-24 WO PCT/US2013/022870 patent/WO2013116075A1/en active Application Filing
- 2013-01-24 MX MX2014008599A patent/MX2014008599A/es unknown
- 2013-01-24 ES ES13703234.8T patent/ES2590929T3/es active Active
- 2013-01-24 EP EP13703234.8A patent/EP2809651B1/en active Active
- 2013-01-24 AU AU2013215468A patent/AU2013215468A1/en not_active Abandoned
- 2013-01-24 CN CN201380007085.XA patent/CN104066719B/zh active Active
- 2013-01-24 US US13/748,627 patent/US8575352B2/en not_active Expired - Fee Related
- 2013-01-24 SG SG11201404106QA patent/SG11201404106QA/en unknown
- 2013-01-24 BR BR112014018636A patent/BR112014018636A8/pt not_active IP Right Cessation
-
2014
- 2014-06-30 ZA ZA2014/04836A patent/ZA201404836B/en unknown
- 2014-07-04 CR CR20140322A patent/CR20140322A/es unknown
- 2014-07-15 CL CL2014001861A patent/CL2014001861A1/es unknown
- 2014-07-17 IL IL233712A patent/IL233712A0/en unknown
- 2014-07-24 MA MA37244A patent/MA35886B1/fr unknown
- 2014-07-24 CO CO14161422A patent/CO7010839A2/es unknown
- 2014-07-29 GT GT201400167A patent/GT201400167A/es unknown
- 2014-07-30 DO DO2014000178A patent/DOP2014000178A/es unknown
- 2014-07-30 PH PH12014501711A patent/PH12014501711A1/en unknown
- 2014-12-11 HK HK14112466.4A patent/HK1199025A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
TW201343629A (zh) | 2013-11-01 |
IL233712A0 (en) | 2014-09-30 |
AU2013215468A1 (en) | 2014-07-10 |
HK1199025A1 (en) | 2015-06-19 |
DOP2014000178A (es) | 2014-08-31 |
BR112014018636A2 (pt) | 2017-06-20 |
PH12014501711A1 (en) | 2014-10-13 |
ZA201404836B (en) | 2017-08-30 |
MA35886B1 (fr) | 2014-12-01 |
MX2014008599A (es) | 2014-08-22 |
CO7010839A2 (es) | 2014-07-31 |
WO2013116075A1 (en) | 2013-08-08 |
CA2859995A1 (en) | 2013-08-08 |
EP2809651B1 (en) | 2016-06-29 |
US8575352B2 (en) | 2013-11-05 |
CL2014001861A1 (es) | 2014-11-07 |
AP2014007794A0 (en) | 2014-07-31 |
CR20140322A (es) | 2014-08-25 |
GT201400167A (es) | 2015-05-28 |
EA201491276A1 (ru) | 2014-10-30 |
KR20140106750A (ko) | 2014-09-03 |
ES2590929T3 (es) | 2016-11-24 |
CN104066719B (zh) | 2016-08-24 |
PE20141679A1 (es) | 2014-11-08 |
EP2809651A1 (en) | 2014-12-10 |
AR089771A1 (es) | 2014-09-17 |
US20130197039A1 (en) | 2013-08-01 |
CN104066719A (zh) | 2014-09-24 |
JP2015511232A (ja) | 2015-04-16 |
SG11201404106QA (en) | 2014-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014018636A8 (pt) | Derivados de benzil sulfonamida úteis como inibidores de mogat-2 | |
BR112013020996A2 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
BR112017020999A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
BR112014010576B8 (pt) | compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos | |
BR112017027831A2 (pt) | derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os | |
BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
UY35243A (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
BR112014013974A2 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
EA201591455A1 (ru) | Производные бензимидазолона в качестве ингибиторов бромодомена | |
BR112014028042A2 (pt) | inibidores de nampt | |
BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
PH12016501462A1 (en) | Neprilysin inhibitors | |
EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
BR112016001783A2 (pt) | compostos e composições como inibidores de mek | |
BR112014018712A8 (pt) | Derivados de morfolinila úteis como inibidores de mogat-2 | |
BR112013017362A2 (pt) | composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores | |
BR112016022749A2 (pt) | compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2 | |
BR112015009567A2 (pt) | compostos de benzil sulfonamida novos úteis como inibidores de mogat-2 | |
BR112016018418A2 (pt) | Composto, uso do mesmo, e composição farmacêutica | |
BR112018015191A2 (pt) | compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |